E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2

Cancer statistics, 2019

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations

Medicine, Oncology, Pharmacology +17

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

Shinichi Yachida, Siân Jones, Ivana Božić et al. · Nature · 2010 · 2.5K citations

Medicine, Genetics, Oncology +14

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis et al. · Journal of Clinical Oncology · 2010 · 842 citations · Full text

Medicine, Oncology, Pharmacotherapy +11